Alpha Tau Medical Ltd. (DRTS), a clinical-stage oncology company pioneering alpha-radiation cancer therapy, is accelerating its clinical and regulatory progress in 2025, with several U.S. and international trials underway and new FDA approvals setting the stage for a pivotal year.
Q1, 2025 Financial Performance:
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com